Paul Kirschmeier

Affiliations

Dana Farber Cancer Institute, Belfer Institute of Cancer Science, Boston, MA, USA.

Réseau de co-auteurs

Sangeetha Palakurthi 3 collaborations

Juan J Miret 1 collaboration

Shohei Koyama 1 collaboration

Mingrui Zhu 1 collaboration

Yvonne Y Li 1 collaboration

Yujiro Naito 1 collaboration

Min Wu 1 collaboration

Venkat S Malladi 1 collaboration

Wei Huang 1 collaboration

William Walker 1 collaboration

Glenn Dranoff 1 collaboration

Peter S Hammerman 1 collaboration

Chad V Pecot 1 collaboration

Kwok-Kin Wong 1 collaboration

Esra A Akbay 1 collaboration

Atsuko Ogino 1 collaboration

Jihyun Choi 1 collaboration

Mika Lin 1 collaboration

Margaret K Wilkens 1 collaboration

Antonio Calles 1 collaboration

Man Xu 1 collaboration

Anika E Adeni 1 collaboration

Emily S Chambers 1 collaboration

Marzia Capelletti 1 collaboration

Mohit Butaney 1 collaboration

Nathanael S Gray 1 collaboration

Prafulla C Gokhale 1 collaboration

Geoffrey R Oxnard 1 collaboration

Lynette M Sholl 1 collaboration

Pasi A Jänne 1 collaboration

Panagiotis A Konstantinopoulos 1 collaboration

William T Barry 1 collaboration

Michael Birrer 1 collaboration

Shannon N Westin 1 collaboration

Karen A Cadoo 1 collaboration

Geoffrey I Shapiro 1 collaboration

Erica L Mayer 1 collaboration

Roisin E O'Cearbhaill 1 collaboration

Robert L Coleman 1 collaboration

Bose Kochupurakkal 1 collaboration

Christin Whalen 1 collaboration

Jennifer Curtis 1 collaboration

Sarah Farooq 1 collaboration

Weixiu Luo 1 collaboration

Julia Eismann 1 collaboration

Mary K Buss 1 collaboration

Carol Aghajanian 1 collaboration

Gordon B Mills 1 collaboration

Joyce Liu 1 collaboration

Lewis C Cantley 1 collaboration

Scott H Kaufmann 1 collaboration

Elizabeth M Swisher 1 collaboration

Alan D D'Andrea 1 collaboration

Eric Winer 1 collaboration

Gerburg M Wulf 1 collaboration

Ursula A Matulonis 1 collaboration

Paul Kirschmeier

Affiliations

Publications (3)

Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity.

Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.

Réseau de co-auteurs